Breast最新文献

{"title":"Surgeon seniority and performance in breast-conserving surgery for non-palpable lesions: evidence from a multicenter study","authors":"Fabio Corsi MD ,&nbsp;Maria Luisa Gasparri MD, PhD ,&nbsp;Sara Albasini MsC ,&nbsp;Matilde Pelizzola MsC ,&nbsp;Carlo Morasso PhD ,&nbsp;Giulia Armatura MD, PhD ,&nbsp;Alessandro Asaro MD ,&nbsp;Virginia Casati MD ,&nbsp;Corrado Chiappa MD ,&nbsp;Virginia Coli MD ,&nbsp;Francesca Combi MD ,&nbsp;Andrea Cuccaro MD ,&nbsp;Angelica Della Valle MD ,&nbsp;Raimondo Di Giacomo MD ,&nbsp;Secondo Folli MD ,&nbsp;Massimo Maria Grassi MD ,&nbsp;Stefano Mancini MD ,&nbsp;Ilaria Maugeri MD ,&nbsp;Andrea Papadia MD, PhD ,&nbsp;Laura Roveda MD ,&nbsp;Simone Zanotti MD","doi":"10.1016/j.breast.2026.104736","DOIUrl":"10.1016/j.breast.2026.104736","url":null,"abstract":"<div><div>Breast-conserving surgery (BCS) for non-palpable lesions is technically demanding, often performed by surgical trainees under supervision. Despite extensive literature evaluating localization techniques, only few studies have directly examined the role of surgeon seniority in determining surgical performance in this specific setting.</div><div>We conducted a retrospective multicenter analysis (LOCALIZATION01 study, NCT05942105) including 3,195 patients who underwent BCS for non-palpable breast lesions between 2016 and 2024 across 12 Breast Units. Four localization techniques were used: wire-guided (WGL), radioguided occult lesion localization (ROLL), magnetic seed localization (MSL), carbon localization (CL). Outcomes included margin status, calculated resection ratio (CRR), operative time, and complications, stratified by surgeon seniority (attending vs resident).</div><div>Most procedures were performed by attending surgeons (89.3%, n = 2,855) compared to residents (10.7%, n = 340). Margin positivity rates didn't differ significantly across localization techniques (e.g., ROLL 3.7% vs 2.3%, p = 0.30; MSL 9.4% vs 4.4%, p = 0.11, WGL 2.7% vs 5.9 p = 0.16, CL 0% vs 9.6% p = 0.10). Residents achieved better CRR in ROLL procedures (2.0, IQR 3, [1-47] vs 2.8, IQR 5, [1-78], p = 0.006), but had longer operative times, particularly with SLNB (e.g., MSL 60 min, IQR 31, [37-98] vs 55 min, IQR 20, [18−180], p = 0.02). Complication rates were low and comparable between groups.</div><div>In a supervised setting, surgeon seniority doesn't significantly impact margin status, complication rates, or overall oncologic safety in BCS for non-palpable breast lesions. Localization methods with high reproducibility, such as ROLL and MSL, may mitigate the influence of surgical inexperience. These findings support the safe involvement of trainees in BCS under adequate supervision.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"86 ","pages":"Article 104736"},"PeriodicalIF":7.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146185281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness comparison of first-line CDK4/6 inhibitors in patients with hormone-positive HER2-negative advanced breast cancer according to tumor histology: a sub-analysis of the real-world, multicenter, Italian study PALMARES-2","authors":"Giacomo Mazzoli ,&nbsp;Leonardo Provenzano ,&nbsp;Maria Vittoria Dieci ,&nbsp;Giuseppe Curigliano ,&nbsp;Mario Giuliano ,&nbsp;Andrea Botticelli ,&nbsp;Matteo Lambertini ,&nbsp;Gianpiero Rizzo ,&nbsp;Rebecca Pedersini ,&nbsp;Marianna Sirico ,&nbsp;Nicla La Verde ,&nbsp;Alessandra Gennari ,&nbsp;Alberto Zambelli ,&nbsp;Angela Toss ,&nbsp;Marta Piras ,&nbsp;Monica Giordano ,&nbsp;Barbara Tagliaferri ,&nbsp;Daniele Generali ,&nbsp;Donata Sartori ,&nbsp;Giuseppe Fotia ,&nbsp;Claudio Vernieri","doi":"10.1016/j.breast.2026.104692","DOIUrl":"10.1016/j.breast.2026.104692","url":null,"abstract":"<div><h3>Introduction</h3><div>Invasive lobular breast cancer (ILC) is the second most common breast cancer subtype, with distinctive biological and epidemiologic features. Although phase III trials of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in hormone receptor-positive, HER2-negative advanced breast cancer (HR+/HER2-aBC) included patients with ILC, their real-world effectiveness in this population remains poorly characterized.</div></div><div><h3>Material and methods</h3><div>In this sub-analysis of the multicenter, real-world PALMARES-2 study (NCT06805812), we assessed the predictive and prognostic value of lobular histology in HR+/HER2-aBC treated with first-line endocrine therapy (ET) plus CDK4/6i. The primary endpoint was real-world progression-free survival (rwPFS). Associations between histology and outcomes were adjusted for 15 covariates using multivariable Cox-regression and inverse probability of treatment weighting.</div></div><div><h3>Results</h3><div>Among 1982 patients, 367 (18.5 %) had ILC and 1481 (74.7 %) non-special type (NST). Median follow-up was 29.8 and 31.2 months, respectively. ILC was associated with shorter rwPFS versus NST (adjusted hazard ratio [aHR]: 1.24, 95 %CI:1.04–1.47, <em>P=</em>0.017). Palbociclib efficacy was not affected by lobular histology (<em>P</em> for interaction = 0.553) while abemaciclib was less effective in ILC (<em>P</em> = 0.009). All three CDK4/6i achieved similar rwPFS in ILC (ribociclib vs palbociclib: aHR: 1.01, 95 %CI: 0.67–1.45, <em>P</em> = 0.949; abemaciclib vs palbociclib: aHR: 1.13, 95 %CI: 0.75–1.71, <em>P</em> = 0.551; abemaciclib vs ribociclib: aHR: 1.15, 95 %CI: 0.73–1.80, <em>P</em> = 0.549).</div></div><div><h3>Conclusions</h3><div>Tumor histology affects the real-world effectiveness of first line ET plus CDK4/6i. In ILC, all three CDK4/6i performed similarly; therefore, treatment selection should prioritize tolerability, manageability, drug-drug interactions, and patient preferences.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"86 ","pages":"Article 104692"},"PeriodicalIF":7.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146075841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Subcutaneous pertuzumab–trastuzumab: Efficiency, safety, and the biosimilar horizon","authors":"Asim Armagan Aydin ,&nbsp;Erkan Kayikcioglu","doi":"10.1016/j.breast.2025.104651","DOIUrl":"10.1016/j.breast.2025.104651","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"86 ","pages":"Article 104651"},"PeriodicalIF":7.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145582103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nivolumab in combination with ipilimumab versus capecitabine as post-operative treatment for triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy: a multicentre, randomized, open-label phase II trial – BREASTIMMUNE-03","authors":"Olivier Trédan ,&nbsp;Delphine Loirat ,&nbsp;Sylvie Chabaud ,&nbsp;Philippe Toussaint ,&nbsp;Thierry Petit ,&nbsp;Frédéric Viret ,&nbsp;Christelle Levy ,&nbsp;Aurélien Robert ,&nbsp;Julien Grenier ,&nbsp;Laura Mansi ,&nbsp;Jean-Philippe Spano ,&nbsp;Anne Patsouris ,&nbsp;Olfa Derbel ,&nbsp;Christelle Jouannaud ,&nbsp;Jean Marc Ferrero ,&nbsp;Jean Sébastien Frenel ,&nbsp;Yann Molin ,&nbsp;Louis Doublet ,&nbsp;Pierre-Etienne Heudel ,&nbsp;Jean-Yves Pierga ,&nbsp;Thomas Bachelot","doi":"10.1016/j.breast.2025.104648","DOIUrl":"10.1016/j.breast.2025.104648","url":null,"abstract":"<div><h3>Background</h3><div>Triple negative breast cancer (TNBC) patients with residual disease after neoadjuvant chemotherapy (NAC) face high risk of recurrence. BREASTIMMUNE-03 trial evaluates the efficacy of nivolumab and ipilimumab combination compared to capecitabine as adjuvant treatment.</div></div><div><h3>Methods</h3><div>This multicentre, randomized open-label phase II trial included TNBC patients with Residual Cancer Burden (RCB) of class II-III after NAC and surgery, and allocated them to randomization (1:1) to receive nivolumab plus ipilimumab or capecitabine for 24 weeks. Randomization was stratified by center, ECOG performance status (PS) 0 or 1, and RCB Class. Primary endpoint was disease free survival (DFS), assessed in the intent-to-treat population. Safety analysis according to NCI-CTCAE V5.0 included all patients who received at least one dose of study drug.</div></div><div><h3>Results</h3><div>From July 2019 to October 2021, 95 patients were randomized to the nivolumab plus ipilimumab arm (NIVO + IPI n = 45), or to the capecitabine arm (CT n = 50). With a median follow-up of 34.3 (IQR 33–36) months, 39 events (relapse or death) were reported: 17 (38 %) for NIVO + IPI; 22 (44 %) for CT (HR 0.84, 95 %CI 0.45–1.59; log-rank test p-value 0.5938). 17 (38 %) patients in the NIVO + IPI arm prematurely discontinued treatment due to treatment-related adverse events (AEs), <em>versus</em> 7 (14 %) in the CT arm.</div></div><div><h3>Conclusion</h3><div>A 6-month post-operative nivolumab plus ipilimumab treatment did not significantly improve DFS compared to capecitabine in TNBC patients with RCB II-III and resulted in increased immune-mediated AEs. Despite premature trial termination, our results do not support nivolumab plus ipilimumab adjuvant treatment in this setting.</div></div><div><h3>Trial registration</h3><div>NCT03818685.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"85 ","pages":"Article 104648"},"PeriodicalIF":7.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145615858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world outcomes with palbociclib, ribociclib, and abemaciclib plus endocrine therapy in HR+/HER2− advanced breast cancer: A multicenter retrospective study","authors":"Renata Duchnowska ,&nbsp;Katarzyna Soter ,&nbsp;Katarzyna Pogoda ,&nbsp;Jolanta Smok-Kalwat ,&nbsp;Aleksandra Grela-Wojewoda ,&nbsp;Karolina Winsko-Szczęsnowicz ,&nbsp;Agnieszka Kowalewska-Felczak ,&nbsp;Marek Szwiec ,&nbsp;Iwona Danielewicz ,&nbsp;Joanna Streb ,&nbsp;Tomasz Lewandowski ,&nbsp;Bartosz Szymanowski ,&nbsp;Joanna Kiszka ,&nbsp;Barbara Radecka ,&nbsp;Ewa Kalinka ,&nbsp;Bartosz K. Sobocki ,&nbsp;Maria Litwiniuk ,&nbsp;Aleksandra Łacko ,&nbsp;Anna Bałata ,&nbsp;Justyna Żubrowska ,&nbsp;Jacek Jassem","doi":"10.1016/j.breast.2025.104665","DOIUrl":"10.1016/j.breast.2025.104665","url":null,"abstract":"<div><h3>Background</h3><div>Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) are the standard first- and second-line treatments for hormone receptor-positive (HR+), HER2-negative (HER2−) advanced breast cancer (ABC). Real-world data (RWD) may inform the optimal use of these agents in routine practice.</div></div><div><h3>Patients and methods</h3><div>The multicenter, population-based POLiCDK study compared progression-free survival (PFS), second PFS, and overall survival (OS) in ABC patients with HR+/HER2− ABC treated with palbociclib (PAL), ribociclib (RIB), or abemaciclib (ABE) in first- or second-line ET settings at 16 Polish centers between September 2017 and January 2025. Analyses were stratified by endocrine sensitivity/resistance, and stabilized inverse probability of treatment weighting was used to balance baseline characteristics.</div></div><div><h3>Results</h3><div>Among 2063 patients (701 PAL, 968 RIB, 394 ABE), 1583 (76.7 %) received CDK4/6i in the first-line and 480 (23.3 %) in the second-line setting. Overall, 927 (44.9 %) had <em>de novo</em> ABC; 819 (39.7 %) were endocrine-naïve, 158 (8.9 %) primary resistant, and 808 (39.2 %) secondary resistant. Median follow-up was 35.9, 24.1, and 21.4 months for PAL, RIB, and ABE, respectively. In endocrine-naïve patients, PFS did not differ significantly between CDK4/6i combined with aromatase inhibitors (AIs). In secondary endocrine-resistant disease, RIB and ABE outperformed PAL with AI combinations, whereas outcomes with fulvestrant were similar. In second-line therapy, all three CDK4/6i showed comparable results. Adjusted hazard ratios confirmed these trends without consistent superiority of any single agent.</div></div><div><h3>Conclusions</h3><div>Endocrine sensitivity/resistance and ET partner were major determinants of outcome with CDK4/6i plus ET in HR+/HER2− ABC, informing individualized treatment selection and sequencing.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"85 ","pages":"Article 104665"},"PeriodicalIF":7.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145615859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Korean nationwide analysis of male breast Cancer: Incidence trends, treatment disparities, and survival compared with female patients","authors":"Jiyeong Kim ,&nbsp;Shin Jeong Pak ,&nbsp;Min Sung Chung ,&nbsp;Chihwan David Cha","doi":"10.1016/j.breast.2025.104680","DOIUrl":"10.1016/j.breast.2025.104680","url":null,"abstract":"<div><h3>Background</h3><div>s: Male breast cancer (MBC) accounts for less than 1 % of all breast cancer cases and is considered a rare disease. However, its incidence is steadily increasing. Despite this trend, comprehensive analyses comparing the clinicopathological characteristics and outcomes between male and female breast cancer (FBC) patients remain limited.</div></div><div><h3>Methods</h3><div>Using Korean National Health Insurance data (2007–2023), we analyzed 368,577 patients (1437 men; 367,140 women). Age-standardized incidence rates (ASR), clinicopathological features (age at diagnosis, Charlson Comorbidity Index), treatment modalities, recurrence rates, and mortality outcomes were compared between MBC and FBC. Multivariate Cox proportional hazards regression was performed to assess the association of sex with recurrence and survival.</div></div><div><h3>Results</h3><div>ASR of MBC doubled (0.59–1.19), while female breast cancer (FBC) increased from 67.6 to 157.3. Male patients were older at diagnosis (64 vs. 51 years, p &lt; 0.001), had higher comorbidity (p &lt; 0.001), and showed worse outcomes. Recurrence was more frequent in men (14.3 % vs. 12.5 %, p = 0.038) as was mortality (31.3 % vs. 11.1 %, p &lt; 0.001). Multivariate analysis confirmed male sex as a significant risk factor for recurrence (p = 0.010).</div></div><div><h3>Conclusion</h3><div>Despite its rarity, MBC incidence is increasing, with distinct clinicopathological features and poorer prognosis compared to FBC. These findings emphasize the need for sex-specific strategies and inclusion of male patients in breast cancer research.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"85 ","pages":"Article 104680"},"PeriodicalIF":7.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145910403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoadjuvant endocrine therapy with sequential palbociclib and chemotherapy based on Ki67 status in stage II-III breast cancer: An open-label, phase II study","authors":"Christina Engebrethsen ,&nbsp;Synnøve Yndestad ,&nbsp;Mari E. Rasmussen ,&nbsp;Emiel A.M. Janssen ,&nbsp;Bjørnar Gilje ,&nbsp;Egil S. Blix ,&nbsp;Helge Espelid ,&nbsp;Steinar Lundgren ,&nbsp;Jürgen Geisler ,&nbsp;Laura Minsaas ,&nbsp;Reidun Lillestøl ,&nbsp;Hildegunn S. Aase ,&nbsp;Turid Aas ,&nbsp;Per E. Lønning ,&nbsp;Hans P. Eikesdal ,&nbsp;Stian Knappskog","doi":"10.1016/j.breast.2025.104672","DOIUrl":"10.1016/j.breast.2025.104672","url":null,"abstract":"<div><h3>Background</h3><div>While neoadjuvant endocrine therapy (NET), with or without a CDK4/6 inhibitor, is an established treatment option for estrogen receptor-positive breast cancers, optimal patient selection and second-line treatment for non-responders remain uncertain.</div></div><div><h3>Methods</h3><div>In the open-label, phase 2 PETREMAC trial (NCT02624973), pre- and postmenopausal patients with large T2 (&gt;4 cm) or locally advanced ER/PGR&gt;50 %, HER2-, and <em>TP53</em> wild-type breast cancers received NET (tamoxifen + goserelin for premenopausal and letrozole for postmenopausal patients). Palbociclib was added if the Ki67 reduction was ≤50 % after 14 days. Neoadjuvant chemotherapy (NAC) was introduced if NET ± palbociclib failed to reduce Ki67 sufficiently or if there was no objective response on MRI after 24 weeks. Tumor biopsies underwent targeted sequencing of 360 cancer-related genes and subsequent gene expression profiling.</div></div><div><h3>Results</h3><div>Among 88 patients, the median tumor size was 48 mm (range 16–140 mm). NET alone reduced Ki67 &gt; 50 % in 49/88 (56 %) of evaluable tumors. Adding palbociclib yielded a Ki67 reduction &gt;50 % in 24/34 (71 %) of tumors where neoadjuvant endocrine therapy alone failed to suppress Ki67, providing a Ki67 reduction of &gt;50 % in a total of 72/88 (82 %) of patients. NAC was administered to 34/88 (39 %) due to inadequate Ki67 response or lack of MRI response. Overall, 70 % achieved a pre-surgical objective response. Pathological complete response was seen in 3/84 patients. Postmenopausal status (p = 0.005) and invasive lobular carcinoma (p = 0.02) predicted Ki67-based response to NET.</div></div><div><h3>Conclusion</h3><div>Sequential NET with palbociclib, limiting NAC to non-responders, is a feasible strategy for ER/PGR&gt;50 %, HER2-, <em>TP53</em> wild-type breast cancers.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"85 ","pages":"Article 104672"},"PeriodicalIF":7.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145910477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes for ER-positive CHEK2 c.1100delC breast cancer patients compared with breast cancer patients without the variant","authors":"Maartje A.C. Schreurs ,&nbsp;Muriel A. Adank ,&nbsp;Bernadette A.M. Heemskerk-Gerritsen ,&nbsp;Antoinette Hollestelle ,&nbsp;Nyrée Smallenbroek ,&nbsp;Christi J. van Asperen ,&nbsp;Margreet G.E.M. Ausems ,&nbsp;Irma van de Beek ,&nbsp;Geertruida H. de Bock ,&nbsp;Ingrid Boere ,&nbsp;Liselotte P. van Hest ,&nbsp;Kim J.A.F. van Kaam ,&nbsp;Linda de Munck ,&nbsp;Janet R. Vos ,&nbsp;Agnes Jager ,&nbsp;Marjanka K. Schmidt ,&nbsp;Maartje J. Hooning ,&nbsp;Hebon","doi":"10.1016/j.breast.2025.104666","DOIUrl":"10.1016/j.breast.2025.104666","url":null,"abstract":"<div><h3>Purpose</h3><div>Germline <em>CHEK2</em> c.1100delC-associated breast cancer (BC) patients have been reported with worse prognosis than patients without the variant. However, results are based on older cohorts and treatment regimens. As part of the Hebon-CHEK2 study, we aim to study prognosis in a Dutch cohort of genetically tested ER-positive BC patients diagnosed from 2006 onwards.</div></div><div><h3>Methods</h3><div>All patients underwent genetic testing based on personal and family history risk, and data on BC outcomes were collected. Hazard ratios (HRs) and 95 % confidence intervals (CI) for the association of <em>CHEK2</em>-status with prognosis were estimated via delayed entry Cox regression models, adjusted for age and year of diagnosis, tumor size, nodal status, and primary treatment regimens. Furthermore, we meta-analyzed our results with previous studies.</div></div><div><h3>Results</h3><div>We included 480 <em>CHEK2</em> BC patients and 944 BC patients without the variant. Median follow-up was 6.0 years. Heterozygotes were more often diagnosed with small tumors, and lymph node positive disease. No significant difference was found for recurrent disease and distant disease-free survival, neither before 5 years (HR = 0.73; 95 %CI = 0.35–1.53 and HR = 0.99; 95 %CI = 0.44–2.21, respectively), nor after 5 years follow-up (HR = 0.29; 95 %CI = 0.06–1.28 and HR = 0.39; 95 %CI = 0.10–1.39, respectively). Also no significant difference in BC-specific survival (HR = 0.77; 95 %CI = 0.42–1.39) or overall survival (HR = 0.69; 95 %CI = 0.43–1.08) was found. Meta-analysis of our results with previous studies showed a worse BC-specific survival for heterozygotes.</div></div><div><h3>Conclusion</h3><div>In our study, with more recent years of diagnosis and treatment, we found no difference in prognosis, as opposed to previous studies. Further research is needed to validate our findings.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"85 ","pages":"Article 104666"},"PeriodicalIF":7.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145615857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Breast International Group (BIG) Patient Partnership: Embedding meaningful patient involvement in the design and conduct of breast cancer clinical research","authors":"Carmela Caballero ,&nbsp;Virginie Adam ,&nbsp;Orsolya Birta ,&nbsp;Lydie Meheus ,&nbsp;Judy Needham ,&nbsp;Christine Hodgdon ,&nbsp;Leslie Gilhams ,&nbsp;Concepcion Biurrun ,&nbsp;Mairead MacKenzie ,&nbsp;Tanja Spanic ,&nbsp;Hilary Stobart ,&nbsp;Lynda Belhadi ,&nbsp;Julia Maués ,&nbsp;Ana Casas ,&nbsp;Eva Schumacher-Wulf ,&nbsp;Carolyn Straehle ,&nbsp;Seamus O'Reilly ,&nbsp;David Cameron ,&nbsp;Martine Piccart ,&nbsp;Judith Bliss ,&nbsp;Boon Chua","doi":"10.1016/j.breast.2025.104642","DOIUrl":"10.1016/j.breast.2025.104642","url":null,"abstract":"<div><div>Involving those with a lived experience of the relevant condition in the design of clinical research ensures that studies address real-world needs and priorities, enabling more relevant, ethical, and impactful outcomes. In 2019, the Breast International Group (BIG) established the BIG Patient Partnership to facilitate the meaningful involvement of people affected by breast cancer in the design and conduct of its studies. The members provide a strong international patient voice in academic breast cancer research. The partnership is based on 4 pillars: foundational and ongoing training, meaningful and systematic involvement, patients as a strategic driving force in BIG's research, and promoting the value of the patients' voice in research. In this paper, we describe a model to enable performing transnational clinical research for and <em>with</em> patient partners. We hope to inspire organizations and people who are burdened by cancer from different cultural backgrounds to develop an interactive, engaging, and empowering process for researchers and patient partners to work together.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"85 ","pages":"Article 104642"},"PeriodicalIF":7.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145562810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Climate change impacts and sustainability integration among breast international group members” [The Breast Volume 81 June 2025 104469]","authors":"Seamus O'Reilly ,&nbsp;Jessica Griffiths ,&nbsp;Lisa Fox ,&nbsp;Catherine S. Weadick ,&nbsp;Nay My Oo ,&nbsp;Lucy Murphy ,&nbsp;Robert O'Leary ,&nbsp;Theodora Goulioti ,&nbsp;Virginie Adam ,&nbsp;Evangelia D. Razis ,&nbsp;Barbro Lindholm ,&nbsp;Gustavo Werutsky ,&nbsp;David Cameron ,&nbsp;Judith Bliss","doi":"10.1016/j.breast.2025.104653","DOIUrl":"10.1016/j.breast.2025.104653","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"85 ","pages":"Article 104653"},"PeriodicalIF":7.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145547880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}